Search

Your search keyword '"precursor B-lineage acute lymphoblastic leukemia"' showing total 2 results
Start Over Descriptor "precursor B-lineage acute lymphoblastic leukemia" Topic pathology
2 results on '"precursor B-lineage acute lymphoblastic leukemia"'

1. An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia

Author

Nikhil Patkar, P G Subramanian, Prashant Tembhare, Sneha Mandalia, Gaurav Chaterjee, Nikhil Rabade, Rohan Kodgule, Karishma Chopra, Asma Bibi, Swapnali Joshi, Shruti Chaudhary, Russel Mascerhenas, Pratibha Kadam-Amare, Gaurav Narula, Brijesh Arora, Shripad Banavali, and Sumeet Gujral

Subjects
Copy number alteration, minimal residual disease, precursor B-lineage acute lymphoblastic leukemia, Pathology, RB1-214, Microbiology, QR1-502
Abstract

Introduction: Copy number alterations (CNA) have been described in childhood precursor B-lineage acute lymphoblastic leukemia (B-ALL) which in conjunction with chromosomal abnormalities drive leukemogenesis. There is no consensus on the clinical incorporation of CNA in B-ALL. An integrated genomic classification (IGC) has been proposed which includes CNA and cytogenetics. Methods: We correlated this IGC with immunophenotypic minimal residual disease (MRD) as well as other standard criteria for 245 patients of B-ALL such as National Cancer Institute (NCI) risk, D+8 prednisolone response, cytogenetics, and ploidy status. Results: MRD was detectable in 81 patients (33.1%). The most common abnormalities were seen in CDKN2A/B (25.7%) followed by PAX5(20%), ETV6(16.7%), IKZF1(15.5%), Rb1(5.3%), BTG (3.3%), EBF1(2.0%), and PAR1(0.8%). On integrating CNA into the IGC, 170 patients (69.4%) were classified into good genomic risk (GEN-GR) whereas 75 (30.6%) belonged to the poor genomic risk (GEN-PR) category. The IGC showed a significant correlation with MRD and NCI risk. The presence of CNA predicted MRD clearance in intermediate cytogenetics group. Conclusion: These data seem to indicate that in addition to cytogenetics, CNA should be incorporated into routine clinical testing and risk algorithms for B-ALL. The IGC is of prognostic relevance and offers an additional avenue for prognostication and risk-adapted therapy.

Published
2017
Full Text
View/download PDF

2. An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia

Author

Brijesh Arora, Asma Bibi, Swapnali Joshi, Rohan Kodgule, Gaurav Narula, Gaurav Chaterjee, Pratibha Kadam-Amare, Nikhil Rabade, Russel Mascerhenas, Nikhil Patkar, Prashant Tembhare, Sumeet Gujral, Shripad Banavali, Sneha Mandalia, Karishma Chopra, P.G. Subramanian, and Shruti Chaudhary

Subjects
Male, Microbiology (medical), Oncology, medicine.medical_specialty, Pathology, Neoplasm, Residual, Adolescent, Gene Dosage, lcsh:QR1-502, precursor B-lineage acute lymphoblastic leukemia, Biology, Gene dosage, lcsh:Microbiology, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, CDKN2A, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Internal medicine, hemic and lymphatic diseases, medicine, lcsh:Pathology, Humans, Neoplasm, Pathology, Molecular, Child, Infant, Newborn, Cytogenetics, Infant, Cancer, General Medicine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Copy number alteration, medicine.disease, Minimal residual disease, ETV6, Child, Preschool, 030220 oncology & carcinogenesis, Prednisolone, minimal residual disease, Female, 030215 immunology, medicine.drug, lcsh:RB1-214
Abstract

Introduction: Copy number alterations (CNA) have been described in childhood precursor B-lineage acute lymphoblastic leukemia (B-ALL) which in conjunction with chromosomal abnormalities drive leukemogenesis. There is no consensus on the clinical incorporation of CNA in B-ALL. An integrated genomic classification (IGC) has been proposed which includes CNA and cytogenetics. Methods: We correlated this IGC with immunophenotypic minimal residual disease (MRD) as well as other standard criteria for 245 patients of B-ALL such as National Cancer Institute (NCI) risk, D+8 prednisolone response, cytogenetics, and ploidy status. Results: MRD was detectable in 81 patients (33.1%). The most common abnormalities were seen in CDKN2A/B (25.7%) followed by PAX5(20%), ETV6(16.7%), IKZF1(15.5%), Rb1(5.3%), BTG (3.3%), EBF1(2.0%), and PAR1(0.8%). On integrating CNA into the IGC, 170 patients (69.4%) were classified into good genomic risk (GEN-GR) whereas 75 (30.6%) belonged to the poor genomic risk (GEN-PR) category. The IGC showed a significant correlation with MRD and NCI risk. The presence of CNA predicted MRD clearance in intermediate cytogenetics group. Conclusion: These data seem to indicate that in addition to cytogenetics, CNA should be incorporated into routine clinical testing and risk algorithms for B-ALL. The IGC is of prognostic relevance and offers an additional avenue for prognostication and risk-adapted therapy.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results